Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
Posted inGastroenterology news Oncology

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and manageable immunochemotherapy strategy for this high-risk population.
Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
Posted innews Oncology

Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results

The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrahepatic cholangiocarcinoma, surpassing historical gem‑cis cohorts.
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Posted innews Oncology

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and suggests clinical benefit — including signals versus historical second‑line FOLFOX — warranting randomized validation.